BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-5@catalystbrief.girapphe.com
DTSTAMP:20261117T061844Z
LAST-MODIFIED:20261117T061844Z
DTSTART;VALUE=DATE:20261101
DTEND;VALUE=DATE:20261102
SUMMARY:Readout: Merck Sharp & Dohme LLC (MRK) — Pembrolizumab [Nov 2026]
DESCRIPTION:Phase 3 primary completion: Pembrolizumab (MK-3475) with chemor
 adiotherapy in MIBC (KEYNOTE-992).\nSource: https://clinicaltrials.gov/stu
 dy/NCT04634877\nhttps://catalystbrief.girapphe.com/e/5?lang=en\nNot invest
 ment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/5?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-6@catalystbrief.girapphe.com
DTSTAMP:20261117T024426Z
LAST-MODIFIED:20261117T024426Z
DTSTART;VALUE=DATE:20261101
DTEND;VALUE=DATE:20261102
SUMMARY:Readout: Bristol-Myers Squibb (BMY) — Deucravacitinib [Nov 2026]
DESCRIPTION:Phase 3 primary completion: Efficacy and safety of Deucravaciti
 nib in adults with active Sjögren's Syndrome.\nSource: https://clinicaltr
 ials.gov/study/NCT05946941\nhttps://catalystbrief.girapphe.com/e/6?lang=en
 \nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/6?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-44@catalystbrief.girapphe.com
DTSTAMP:20261117T061550Z
LAST-MODIFIED:20261117T061550Z
DTSTART;VALUE=DATE:20261101
DTEND;VALUE=DATE:20261102
SUMMARY:Readout: Han Xu\, M.D.\, Ph.D.\, FAPCR\, Medical Director\,\, IRB C
 hair — ETOPOSIDE - Usual [Nov 2026]
DESCRIPTION:Phase 3 primary completion: Pharmacogenomics ANDA SNP Clinical 
 Study - Etoposide and Single Nucleotide Polymorphisms.\nSource: https://cl
 inicaltrials.gov/study/NCT01064466\nhttps://catalystbrief.girapphe.com/e/4
 4?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/44?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-54@catalystbrief.girapphe.com
DTSTAMP:20261117T061551Z
LAST-MODIFIED:20261117T061551Z
DTSTART;VALUE=DATE:20261101
DTEND;VALUE=DATE:20261102
SUMMARY:Readout: EMD Serono Research & Development Institute\, Inc. — Ave
 lumab [Nov 2026]
DESCRIPTION:Phase 3 primary completion: Avelumab Program Rollover Study.\nS
 ource: https://clinicaltrials.gov/study/NCT03815643\nhttps://catalystbrief
 .girapphe.com/e/54?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/54?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-92@catalystbrief.girapphe.com
DTSTAMP:20261117T061557Z
LAST-MODIFIED:20261117T061557Z
DTSTART;VALUE=DATE:20261101
DTEND;VALUE=DATE:20261102
SUMMARY:Readout: Han Xu\, M.D.\, Ph.D.\, FAPCR\, Sponsor-Investigator\, IRB
  Chair — Abiraterone - Usual [Nov 2026]
DESCRIPTION:Phase 3 primary completion: Pharmacogenomics IND Commercial SNP
  Clinical Study - Abiraterone and Single Nucleotide Polymorphisms.\nSource
 : https://clinicaltrials.gov/study/NCT03348670\nhttps://catalystbrief.gira
 pphe.com/e/92?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/92?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-7@catalystbrief.girapphe.com
DTSTAMP:20261117T024426Z
LAST-MODIFIED:20261117T024426Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Innovent Biologics (Suzhou) Co. Ltd. — IBI362 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: IBI362 vs semaglutide in overweight
  or obese adults with MAFLD.\nSource: https://clinicaltrials.gov/study/NCT
 06884293\nhttps://catalystbrief.girapphe.com/e/7?lang=en\nNot investment a
 dvice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/7?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-8@catalystbrief.girapphe.com
DTSTAMP:20261117T024426Z
LAST-MODIFIED:20261117T024426Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: AskGene Pharma\, Inc. — ASKB589 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: ASKB589 with CAPOX and PD-1 inhibit
 or in advanced or metastatic GC/GEJ adenocarcinoma.\nSource: https://clini
 caltrials.gov/study/NCT06206733\nhttps://catalystbrief.girapphe.com/e/8?la
 ng=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/8?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-9@catalystbrief.girapphe.com
DTSTAMP:20261117T024426Z
LAST-MODIFIED:20261117T024426Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Janssen Research & Development\, LLC (JNJ) — Cetrelimab 
 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: TAR-200 in combination with Cetreli
 mab vs chemoradiotherapy in MIBC.\nSource: https://clinicaltrials.gov/stud
 y/NCT04658862\nhttps://catalystbrief.girapphe.com/e/9?lang=en\nNot investm
 ent advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/9?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-10@catalystbrief.girapphe.com
DTSTAMP:20261117T024426Z
LAST-MODIFIED:20261117T024426Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Cloudbreak Therapeutics\, LLC — CBT-001 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Safety and efficacy of CBT-001 in p
 atients with pterygium.\nSource: https://clinicaltrials.gov/study/NCT05456
 425\nhttps://catalystbrief.girapphe.com/e/10?lang=en\nNot investment advic
 e. Dates may change.
URL:https://catalystbrief.girapphe.com/e/10?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-13@catalystbrief.girapphe.com
DTSTAMP:20261117T061545Z
LAST-MODIFIED:20261117T061545Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. — AK10
 5 Injection [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Phase III Clinical Trial of AK105
  Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib
  in Subjects With Advanced Hepatocellular Carcinoma (HCC).\nSource: https:
 //clinicaltrials.gov/study/NCT04344158\nhttps://catalystbrief.girapphe.com
 /e/13?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/13?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-21@catalystbrief.girapphe.com
DTSTAMP:20261117T061546Z
LAST-MODIFIED:20261117T061546Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Cook MyoSite — Iltamiocel [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Iltamiocel Compared to Placebo for 
 Chronic Fecal Incontinence in Females With Obstetric Injury.\nSource: http
 s://clinicaltrials.gov/study/NCT05776277\nhttps://catalystbrief.girapphe.c
 om/e/21?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/21?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-27@catalystbrief.girapphe.com
DTSTAMP:20261117T061547Z
LAST-MODIFIED:20261117T061547Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Guangdong Hengrui Pharmaceutical Co.\, Ltd — SHR-1819 In
 jection [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Clinical Study Evaluating the Eff
 icacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic 
 Rhinitis.\nSource: https://clinicaltrials.gov/study/NCT07688772\nhttps://c
 atalystbrief.girapphe.com/e/27?lang=en\nNot investment advice. Dates may c
 hange.
URL:https://catalystbrief.girapphe.com/e/27?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-30@catalystbrief.girapphe.com
DTSTAMP:20261117T061548Z
LAST-MODIFIED:20261117T061548Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: BeOne Medicines — Zanubrutinib [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study to Evaluate Long-term Safet
 y of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Pa
 rticipated in BeiGene Parent Studies of Zanubrutinib.\nSource: https://cli
 nicaltrials.gov/study/NCT04170283\nhttps://catalystbrief.girapphe.com/e/30
 ?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/30?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-32@catalystbrief.girapphe.com
DTSTAMP:20261117T061548Z
LAST-MODIFIED:20261117T061548Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Ausper Biopharma Co.\, Ltd. — AHB-137 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Study of AHB-137 in Participants Wi
 th Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AU
 SHINE).\nSource: https://clinicaltrials.gov/study/NCT07246889\nhttps://cat
 alystbrief.girapphe.com/e/32?lang=en\nNot investment advice. Dates may cha
 nge.
URL:https://catalystbrief.girapphe.com/e/32?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-35@catalystbrief.girapphe.com
DTSTAMP:20261117T061548Z
LAST-MODIFIED:20261117T061548Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: TransThera Sciences (Nanjing)\, Inc. — Tinengotinib 8 mg
  [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Study of Tinengotinib VS. Physician
 's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma.
 \nSource: https://clinicaltrials.gov/study/NCT05948475\nhttps://catalystbr
 ief.girapphe.com/e/35?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/35?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-36@catalystbrief.girapphe.com
DTSTAMP:20261117T061843Z
LAST-MODIFIED:20261117T061843Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Sichuan Kelun-Biotech Biopharmaceutical Co.\, Ltd. — SKB
 264 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study of SKB264 in Combination Wi
 th Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor
  Receptor (EGFR) Mutations\, Locally Advanced or Metastatic Non-Squamous N
 on-Small Cell Lung Cancer.\nSource: https://clinicaltrials.gov/study/NCT06
 711900\nhttps://catalystbrief.girapphe.com/e/36?lang=en\nNot investment ad
 vice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/36?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-38@catalystbrief.girapphe.com
DTSTAMP:20261117T061549Z
LAST-MODIFIED:20261117T061549Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: RayzeBio\, Inc. — RYZ101 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Study of RYZ101 Compared With SOC i
 n Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed F
 ollowing 177Lu-SSA Therapy.\nSource: https://clinicaltrials.gov/study/NCT0
 5477576\nhttps://catalystbrief.girapphe.com/e/38?lang=en\nNot investment a
 dvice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/38?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-41@catalystbrief.girapphe.com
DTSTAMP:20261117T061549Z
LAST-MODIFIED:20261117T061549Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Shanghai JMT-Bio Inc. — KN026 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Phase III Study of KN026 in Combi
 nation With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Lo
 cally Advanced HER2-Positive Breast Cancer.\nSource: https://clinicaltrial
 s.gov/study/NCT06747338\nhttps://catalystbrief.girapphe.com/e/41?lang=en\n
 Not investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/41?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-45@catalystbrief.girapphe.com
DTSTAMP:20261117T061550Z
LAST-MODIFIED:20261117T061550Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: AbbVie — Lutikizumab [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study to Assess Disease Activity 
 and Safety of Lutikizumab in Adult and Adolescent Participants With Modera
 te to Severe Hidradenitis Suppurativa.\nSource: https://clinicaltrials.gov
 /study/NCT06468228\nhttps://catalystbrief.girapphe.com/e/45?lang=en\nNot i
 nvestment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/45?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-50@catalystbrief.girapphe.com
DTSTAMP:20261117T061551Z
LAST-MODIFIED:20261117T061551Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Atea Pharmaceuticals\, Inc. — Bemnifosbuvir-Ruzasvir [De
 c 2026]
DESCRIPTION:Phase 3 primary completion: C-Forward: Efficacy and Safety of B
 EM/RZR vs SOF/VEL in Subjects With Chronic HCV.\nSource: https://clinicalt
 rials.gov/study/NCT07037277\nhttps://catalystbrief.girapphe.com/e/50?lang=
 en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/50?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-51@catalystbrief.girapphe.com
DTSTAMP:20261117T061551Z
LAST-MODIFIED:20261117T061551Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: AbbVie — ABBV-RGX-314 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Pivotal 1 Study of ABBV-RGX-314 (Al
 so Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One
  Time in Participants With nAMD.\nSource: https://clinicaltrials.gov/study
 /NCT04704921\nhttps://catalystbrief.girapphe.com/e/51?lang=en\nNot investm
 ent advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/51?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-53@catalystbrief.girapphe.com
DTSTAMP:20261117T061551Z
LAST-MODIFIED:20261117T061551Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Ipsen — Corabotase [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study to Assess the Effectiveness
  and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lin
 es Between the Eyebrows.\nSource: https://clinicaltrials.gov/study/NCT0742
 7797\nhttps://catalystbrief.girapphe.com/e/53?lang=en\nNot investment advi
 ce. Dates may change.
URL:https://catalystbrief.girapphe.com/e/53?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-55@catalystbrief.girapphe.com
DTSTAMP:20261117T061552Z
LAST-MODIFIED:20261117T061552Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Han Xu\, M.D.\, Ph.D.\, FAPCR\, Sponsor-Investigator\, IRB
  Chair — Raloxifene - Usual [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Bioequivalence ANDA SNP Clinical St
 udy - Raloxifene and Single Nucleotide Polymorphisms.\nSource: https://cli
 nicaltrials.gov/study/NCT06062810\nhttps://catalystbrief.girapphe.com/e/55
 ?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/55?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-56@catalystbrief.girapphe.com
DTSTAMP:20261117T061552Z
LAST-MODIFIED:20261117T061552Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Suzhou Suncadia Biopharmaceuticals Co.\, Ltd. — SHR-A200
 9 monotherapy [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study of SHR-A2009 Versus Platinu
 m-based Chemotherapy in EGFR-mutated\, Advanced or Metastatic NSCLC.\nSour
 ce: https://clinicaltrials.gov/study/NCT06671379\nhttps://catalystbrief.gi
 rapphe.com/e/56?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/56?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-60@catalystbrief.girapphe.com
DTSTAMP:20261117T061552Z
LAST-MODIFIED:20261117T061552Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Clarity Pharmaceuticals Ltd — 64Cu-SAR-bisPSMA [Dec 2026
 ]
DESCRIPTION:Phase 3 primary completion: 64Cu-SAR-bisPSMA Positron Emission 
 Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of
  Prostate Cancer.\nSource: https://clinicaltrials.gov/study/NCT06970847\nh
 ttps://catalystbrief.girapphe.com/e/60?lang=en\nNot investment advice. Dat
 es may change.
URL:https://catalystbrief.girapphe.com/e/60?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-62@catalystbrief.girapphe.com
DTSTAMP:20261117T061553Z
LAST-MODIFIED:20261117T061553Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Teva Branded Pharmaceutical Products R&D LLC — TEV-56248
  [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study to Test if a Fixed-Dose Com
 bination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preve
 nting Asthma Exacerbations.\nSource: https://clinicaltrials.gov/study/NCT0
 6052267\nhttps://catalystbrief.girapphe.com/e/62?lang=en\nNot investment a
 dvice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/62?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-63@catalystbrief.girapphe.com
DTSTAMP:20261117T061553Z
LAST-MODIFIED:20261117T061553Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. — TQB3
 616 capsules\, Letrozole\, Anastrozole\, Tamoxifen [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Clinical Study on Adjuvant Therapy 
 of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined 
 With Endocrine Therapy in Patients With Breast Cancer.\nSource: https://cl
 inicaltrials.gov/study/NCT05780567\nhttps://catalystbrief.girapphe.com/e/6
 3?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/63?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-71@catalystbrief.girapphe.com
DTSTAMP:20261117T061554Z
LAST-MODIFIED:20261117T061554Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Innovent Biologics (Suzhou) Co. Ltd. — Irinotecan OR Pac
 litaxel or Trifluridine/tipiracil（ FTD/TPI） [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Multicenter\, Phase 3 Study of IB
 I343 Monotherapy Versus Treatment of Investigator's Choice in Subjects Wit
 h Previously Treated\, Claudin (CLDN) 18.2-positive\, HER2-negative\, Gast
 ric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001).\nSource: htt
 ps://clinicaltrials.gov/study/NCT06238843\nhttps://catalystbrief.girapphe.
 com/e/71?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/71?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-72@catalystbrief.girapphe.com
DTSTAMP:20261117T061554Z
LAST-MODIFIED:20261117T061554Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Dr. Falk Pharma GmbH — Budesonide [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Once Daily Versus Twice Daily Budes
 onide Orodispersible Tablets for Induction of Remission in EoE.\nSource: h
 ttps://clinicaltrials.gov/study/NCT06596252\nhttps://catalystbrief.girapph
 e.com/e/72?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/72?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-73@catalystbrief.girapphe.com
DTSTAMP:20261117T061554Z
LAST-MODIFIED:20261117T061554Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Sound Pharmaceuticals\, Incorporated — Ebselen [Dec 2026
 ]
DESCRIPTION:Phase 3 primary completion: SPI-1005 for the Treatment of Menie
 re's Disease (Open Label).\nSource: https://clinicaltrials.gov/study/NCT06
 859788\nhttps://catalystbrief.girapphe.com/e/73?lang=en\nNot investment ad
 vice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/73?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-76@catalystbrief.girapphe.com
DTSTAMP:20261117T061555Z
LAST-MODIFIED:20261117T061555Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Jiangsu HengRui Medicine Co.\, Ltd. — SHR0302 tablets、
 Placebo [Dec 2026]
DESCRIPTION:Phase 3 primary completion: To Evaluate the Efficacy and Safety
  of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis.\nSource: htt
 ps://clinicaltrials.gov/study/NCT04957550\nhttps://catalystbrief.girapphe.
 com/e/76?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/76?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-77@catalystbrief.girapphe.com
DTSTAMP:20261117T061555Z
LAST-MODIFIED:20261117T061555Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Incyte Corporation — Povorcitinib [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study to Evaluate the Long-Term S
 afety and Efficacy of Povorcitinib in Participants With Moderate to Severe
  Hidradenitis Suppurativa.\nSource: https://clinicaltrials.gov/study/NCT06
 212999\nhttps://catalystbrief.girapphe.com/e/77?lang=en\nNot investment ad
 vice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/77?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-81@catalystbrief.girapphe.com
DTSTAMP:20261117T061556Z
LAST-MODIFIED:20261117T061556Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Sichuan Baili Pharmaceutical Co.\, Ltd. — BL-B01D1 [Dec 
 2026]
DESCRIPTION:Phase 3 primary completion: A Study Comparing BL-B01D1 With Doc
 etaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR W
 ild-type Non-small Cell Lung Cancer(PANKU-Lung02).\nSource: https://clinic
 altrials.gov/study/NCT06382129\nhttps://catalystbrief.girapphe.com/e/81?la
 ng=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/81?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-82@catalystbrief.girapphe.com
DTSTAMP:20261117T061556Z
LAST-MODIFIED:20261117T061556Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: CanariaBio Inc. — Oregovomab [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Oregovomab Plus Chemo in Newly Diag
 nosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal D
 ebulking Surgery.\nSource: https://clinicaltrials.gov/study/NCT04498117\nh
 ttps://catalystbrief.girapphe.com/e/82?lang=en\nNot investment advice. Dat
 es may change.
URL:https://catalystbrief.girapphe.com/e/82?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-83@catalystbrief.girapphe.com
DTSTAMP:20261117T061556Z
LAST-MODIFIED:20261117T061556Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Biohaven Therapeutics Ltd. — BHV-7000 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study to Determine if BHV-7000 is
  Effective and Safe in Adults With Refractory Focal Onset Epilepsy.\nSourc
 e: https://clinicaltrials.gov/study/NCT06132893\nhttps://catalystbrief.gir
 apphe.com/e/83?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/83?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-90@catalystbrief.girapphe.com
DTSTAMP:20261117T061557Z
LAST-MODIFIED:20261117T061557Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Jiangsu HengRui Medicine Co.\, Ltd. — SHR-A1811 [Dec 202
 6]
DESCRIPTION:Phase 3 primary completion: A Trial of SHR-A1811versus Pyrotini
 b in Combination With Capecitabine in HER2-Positive\, Unresectable and/or 
 Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and 
 Taxane.\nSource: https://clinicaltrials.gov/study/NCT05424835\nhttps://cat
 alystbrief.girapphe.com/e/90?lang=en\nNot investment advice. Dates may cha
 nge.
URL:https://catalystbrief.girapphe.com/e/90?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-94@catalystbrief.girapphe.com
DTSTAMP:20261117T061557Z
LAST-MODIFIED:20261117T061557Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Veradermics\, Inc. — VDPHL01 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Safety and Efficacy of VDPHL01 in M
 ales With AGA.\nSource: https://clinicaltrials.gov/study/NCT06972264\nhttp
 s://catalystbrief.girapphe.com/e/94?lang=en\nNot investment advice. Dates 
 may change.
URL:https://catalystbrief.girapphe.com/e/94?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-104@catalystbrief.girapphe.com
DTSTAMP:20261117T121603Z
LAST-MODIFIED:20261117T121603Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Ipsen — Corabotase [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study to Assess the Effectiveness
  and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkl
 e-like Lines Between the Eyebrows.\nSource: https://clinicaltrials.gov/stu
 dy/NCT07435428\nhttps://catalystbrief.girapphe.com/e/104?lang=en\nNot inve
 stment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/104?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-11@catalystbrief.girapphe.com
DTSTAMP:20261117T061545Z
LAST-MODIFIED:20261117T061545Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Ocular Therapeutix\, Inc. — OTX-TKI [Jan 2027]
DESCRIPTION:Phase 3 primary completion: Study to Evaluate the Efficacy and 
 Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovasc
 ular Age- Related Macular Degeneration.\nSource: https://clinicaltrials.go
 v/study/NCT06495918\nhttps://catalystbrief.girapphe.com/e/11?lang=en\nNot 
 investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/11?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-14@catalystbrief.girapphe.com
DTSTAMP:20261117T061545Z
LAST-MODIFIED:20261117T061545Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Regeneron Pharmaceuticals — Fianlimab [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Trial to See if the Combination o
 f Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing
  or Delaying Melanoma From Coming Back After it Has Been Removed With Surg
 ery.\nSource: https://clinicaltrials.gov/study/NCT05608291\nhttps://cataly
 stbrief.girapphe.com/e/14?lang=en\nNot investment advice. Dates may change
 .
URL:https://catalystbrief.girapphe.com/e/14?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-23@catalystbrief.girapphe.com
DTSTAMP:20261117T061547Z
LAST-MODIFIED:20261117T061547Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Tolmar Inc. — TOL2506 [Jan 2027]
DESCRIPTION:Phase 3 primary completion: Ovarian Suppression Evaluating Subc
 utaneous Leuprolide Acetate in Breast Cancer.\nSource: https://clinicaltri
 als.gov/study/NCT04906395\nhttps://catalystbrief.girapphe.com/e/23?lang=en
 \nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/23?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-24@catalystbrief.girapphe.com
DTSTAMP:20261117T061547Z
LAST-MODIFIED:20261117T061547Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Seagen\, a wholly owned subsidiary of Pfizer — disitamab
  vedotin [Jan 2027]
DESCRIPTION:Phase 3 primary completion: Disitamab Vedotin With Pembrolizuma
 b vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER
 2.\nSource: https://clinicaltrials.gov/study/NCT05911295\nhttps://catalyst
 brief.girapphe.com/e/24?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/24?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-26@catalystbrief.girapphe.com
DTSTAMP:20261117T061547Z
LAST-MODIFIED:20261117T061547Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: IDEAYA Biosciences — IDE196 [Jan 2027]
DESCRIPTION:Phase 3 primary completion: IDE196 (Darovasertib) in Combinatio
 n With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma.\nSou
 rce: https://clinicaltrials.gov/study/NCT05987332\nhttps://catalystbrief.g
 irapphe.com/e/26?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/26?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-29@catalystbrief.girapphe.com
DTSTAMP:20261117T061547Z
LAST-MODIFIED:20261117T061547Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Novo Nordisk A/S — Insulin icodec [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Research Study to See How a Weekl
 y Insulin\, Insulin Icodec\, Helps in Reducing the Blood Sugar Compared to
  Daily Insulin Glargine\, Both in Combination With Insulin Aspart\, in Adu
 lts With Type 1 Diabetes.\nSource: https://clinicaltrials.gov/study/NCT070
 76199\nhttps://catalystbrief.girapphe.com/e/29?lang=en\nNot investment adv
 ice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/29?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-31@catalystbrief.girapphe.com
DTSTAMP:20261117T061548Z
LAST-MODIFIED:20261117T061548Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Hoffmann-La Roche — Afimkibart [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Assess the Efficacy and 
 Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenan
 ce Therapy in Participants With Moderately to Severely Active Ulcerative C
 olitis.\nSource: https://clinicaltrials.gov/study/NCT06589986\nhttps://cat
 alystbrief.girapphe.com/e/31?lang=en\nNot investment advice. Dates may cha
 nge.
URL:https://catalystbrief.girapphe.com/e/31?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-33@catalystbrief.girapphe.com
DTSTAMP:20261117T061548Z
LAST-MODIFIED:20261117T061548Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: AstraZeneca — AZD0780 [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Phase III Study to Assess the Eff
 ect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a F
 irst ASCVD Event.\nSource: https://clinicaltrials.gov/study/NCT07000123\nh
 ttps://catalystbrief.girapphe.com/e/33?lang=en\nNot investment advice. Dat
 es may change.
URL:https://catalystbrief.girapphe.com/e/33?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-40@catalystbrief.girapphe.com
DTSTAMP:20261117T061549Z
LAST-MODIFIED:20261117T061549Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. — TQB2
 102 for Injection [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Clinical Trial of TQB2102 for Inj
 ection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast
  Cancer.\nSource: https://clinicaltrials.gov/study/NCT06561607\nhttps://ca
 talystbrief.girapphe.com/e/40?lang=en\nNot investment advice. Dates may ch
 ange.
URL:https://catalystbrief.girapphe.com/e/40?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-42@catalystbrief.girapphe.com
DTSTAMP:20261117T061549Z
LAST-MODIFIED:20261117T061549Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: AstraZeneca — Dato-DXd [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Investigate the Efficacy
  and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum
  Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Adva
 nced or Metastatic Non-Small Cell Lung Cancer.\nSource: https://clinicaltr
 ials.gov/study/NCT06417814\nhttps://catalystbrief.girapphe.com/e/42?lang=e
 n\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/42?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-48@catalystbrief.girapphe.com
DTSTAMP:20261117T061551Z
LAST-MODIFIED:20261117T061551Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Biocad — BCD-217 [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Study of Neoadjuvant Therapy With
  BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III S
 kin Melanoma.\nSource: https://clinicaltrials.gov/study/NCT05751928\nhttps
 ://catalystbrief.girapphe.com/e/48?lang=en\nNot investment advice. Dates m
 ay change.
URL:https://catalystbrief.girapphe.com/e/48?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-64@catalystbrief.girapphe.com
DTSTAMP:20261117T061553Z
LAST-MODIFIED:20261117T061553Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Pfizer — RSVpreF [Jan 2027]
DESCRIPTION:Phase 3 primary completion: Study to Evaluate the Efficacy\, Im
 munogenicity\, and Safety of RSVpreF in Adults..\nSource: https://clinical
 trials.gov/study/NCT05035212\nhttps://catalystbrief.girapphe.com/e/64?lang
 =en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/64?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-66@catalystbrief.girapphe.com
DTSTAMP:20261117T061553Z
LAST-MODIFIED:20261117T061553Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: ModernaTX\, Inc. — mRNA-1018-H5 [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Study of mRNA-1018-H5 Pandemic In
 fluenza Vaccine in Healthy Adults.\nSource: https://clinicaltrials.gov/stu
 dy/NCT07496450\nhttps://catalystbrief.girapphe.com/e/66?lang=en\nNot inves
 tment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/66?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-68@catalystbrief.girapphe.com
DTSTAMP:20261117T061553Z
LAST-MODIFIED:20261117T061553Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Lexicon Pharmaceuticals — Sotagliflozin [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Evaluate the Efficacy an
 d Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive H
 ypertrophic Cardiomyopathy.\nSource: https://clinicaltrials.gov/study/NCT0
 6481891\nhttps://catalystbrief.girapphe.com/e/68?lang=en\nNot investment a
 dvice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/68?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-74@catalystbrief.girapphe.com
DTSTAMP:20261117T061555Z
LAST-MODIFIED:20261117T061555Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: MoonLake Immunotherapeutics AG — Sonelokimab [Jan 2027]
DESCRIPTION:Phase 3 primary completion: Evaluation of Sonelokimab in Patien
 ts With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response.\nSo
 urce: https://clinicaltrials.gov/study/NCT06641089\nhttps://catalystbrief.
 girapphe.com/e/74?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/74?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-84@catalystbrief.girapphe.com
DTSTAMP:20261117T061556Z
LAST-MODIFIED:20261117T061556Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: AstraZeneca — Durvalumab [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Global Study to Assess the Effect
 s of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Co
 ncurrent Chemoradiation in Patients With Stage III Unresectable Non-Small 
 Cell Lung Cancer.\nSource: https://clinicaltrials.gov/study/NCT05221840\nh
 ttps://catalystbrief.girapphe.com/e/84?lang=en\nNot investment advice. Dat
 es may change.
URL:https://catalystbrief.girapphe.com/e/84?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-89@catalystbrief.girapphe.com
DTSTAMP:20261117T061557Z
LAST-MODIFIED:20261117T061557Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Vertex Pharmaceuticals Incorporated — Suzetrigine [Jan 2
 027]
DESCRIPTION:Phase 3 primary completion: Evaluation of the Long-term Safety 
 and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabet
 ic Peripheral Neuropathy (DPN).\nSource: https://clinicaltrials.gov/study/
 NCT06696443\nhttps://catalystbrief.girapphe.com/e/89?lang=en\nNot investme
 nt advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/89?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-93@catalystbrief.girapphe.com
DTSTAMP:20261117T061557Z
LAST-MODIFIED:20261117T061557Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Xenon Pharmaceuticals Inc. — Azetukalner [Jan 2027]
DESCRIPTION:Phase 3 primary completion: An Open-Label Study of Azetukalner 
 in Major Depressive Disorder.\nSource: https://clinicaltrials.gov/study/NC
 T06922110\nhttps://catalystbrief.girapphe.com/e/93?lang=en\nNot investment
  advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/93?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-97@catalystbrief.girapphe.com
DTSTAMP:20261117T061558Z
LAST-MODIFIED:20261117T061558Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Merck Sharp & Dohme LLC — 9vHPV Vaccine [Jan 2027]
DESCRIPTION:Phase 3 primary completion: Efficacy Against Oral Persistent In
 fection\, Immunogenicity and Safety of the 9-valent Human Papillomavirus V
 accine (9vHPV) in Men Aged 20-45 Years (V503-049).\nSource: https://clinic
 altrials.gov/study/NCT04199689\nhttps://catalystbrief.girapphe.com/e/97?la
 ng=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/97?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-99@catalystbrief.girapphe.com
DTSTAMP:20261117T121546Z
LAST-MODIFIED:20261117T121546Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Merck Sharp & Dohme LLC — Pembrolizumab [Jan 2027]
DESCRIPTION:Phase 3 primary completion: Efficacy and Safety of Pembrolizuma
 b (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone i
 n Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992).\nSource
 : https://clinicaltrials.gov/study/NCT04241185\nhttps://catalystbrief.gira
 pphe.com/e/99?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/99?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-103@catalystbrief.girapphe.com
DTSTAMP:20261117T121556Z
LAST-MODIFIED:20261117T121556Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Amgen — Maridebart Cafraglutide [Jan 2027]
DESCRIPTION:Phase 3 primary completion: Evaluation of Maridebart Cafragluti
 de in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity
  or Are Overweight.\nSource: https://clinicaltrials.gov/study/NCT06858839\
 nhttps://catalystbrief.girapphe.com/e/103?lang=en\nNot investment advice. 
 Dates may change.
URL:https://catalystbrief.girapphe.com/e/103?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-18@catalystbrief.girapphe.com
DTSTAMP:20261117T061546Z
LAST-MODIFIED:20261117T061546Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: Hoffmann-La Roche — Ranibizumab [Feb 2027]
DESCRIPTION:Phase 3 primary completion: A Study of the Efficacy\, Safety\, 
 and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery Sys
 tem With Ranibizumab in Patients With Neovascular Age-Related Macular Dege
 neration (Velodrome).\nSource: https://clinicaltrials.gov/study/NCT0465728
 9\nhttps://catalystbrief.girapphe.com/e/18?lang=en\nNot investment advice.
  Dates may change.
URL:https://catalystbrief.girapphe.com/e/18?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-34@catalystbrief.girapphe.com
DTSTAMP:20261117T061548Z
LAST-MODIFIED:20261117T061548Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: CanSino Biologics Inc. — PCV13i [Feb 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Evaluate the Immunogenic
 ity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Hea
 lthy Infants Aged 2 Months (Minimum 6 Weeks).\nSource: https://clinicaltri
 als.gov/study/NCT07017777\nhttps://catalystbrief.girapphe.com/e/34?lang=en
 \nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/34?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-49@catalystbrief.girapphe.com
DTSTAMP:20261117T061551Z
LAST-MODIFIED:20261117T061551Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: Pfizer — PF-06821497 [Feb 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Learn About the Investig
 ational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who 
 Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVP
 RO-1)..\nSource: https://clinicaltrials.gov/study/NCT06551324\nhttps://cat
 alystbrief.girapphe.com/e/49?lang=en\nNot investment advice. Dates may cha
 nge.
URL:https://catalystbrief.girapphe.com/e/49?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-52@catalystbrief.girapphe.com
DTSTAMP:20261117T061551Z
LAST-MODIFIED:20261117T061551Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: AstraZeneca — Placebo [Feb 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Evaluate the Efficacy\, 
 Safety\, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemi
 a.\nSource: https://clinicaltrials.gov/study/NCT06834932\nhttps://catalyst
 brief.girapphe.com/e/52?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/52?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-58@catalystbrief.girapphe.com
DTSTAMP:20261117T061552Z
LAST-MODIFIED:20261117T061552Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: Celltrion — CT-P51 [Feb 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Compare Effects and Safe
 ty of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic
  Lung Cancer.\nSource: https://clinicaltrials.gov/study/NCT06939595\nhttps
 ://catalystbrief.girapphe.com/e/58?lang=en\nNot investment advice. Dates m
 ay change.
URL:https://catalystbrief.girapphe.com/e/58?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-65@catalystbrief.girapphe.com
DTSTAMP:20261117T061553Z
LAST-MODIFIED:20261117T061553Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: AstraZeneca — Anifrolumab [Feb 2027]
DESCRIPTION:Phase 3 primary completion: Phase 3 Study of Anifrolumab in Adu
 lt Patients With Active Proliferative Lupus Nephritis.\nSource: https://cl
 inicaltrials.gov/study/NCT05138133\nhttps://catalystbrief.girapphe.com/e/6
 5?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/65?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-96@catalystbrief.girapphe.com
DTSTAMP:20261117T061558Z
LAST-MODIFIED:20261117T061558Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: AstraZeneca — Zibotentan/Dapagliflozin [Feb 2027]
DESCRIPTION:Phase 3 primary completion: Study to Investigate Efficacy\, Saf
 ety\, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapaglifloz
 in in Participants With Chronic Kidney Disease and High Proteinuria (ZENIT
 H High Proteinuria).\nSource: https://clinicaltrials.gov/study/NCT06087835
 \nhttps://catalystbrief.girapphe.com/e/96?lang=en\nNot investment advice. 
 Dates may change.
URL:https://catalystbrief.girapphe.com/e/96?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-102@catalystbrief.girapphe.com
DTSTAMP:20261117T121554Z
LAST-MODIFIED:20261117T121554Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: Acerta Pharma BV — acalabrutinib [Feb 2027]
DESCRIPTION:Phase 3 primary completion: A Combination of Acalabrutinib With
  R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312).\
 nSource: https://clinicaltrials.gov/study/NCT04529772\nhttps://catalystbri
 ef.girapphe.com/e/102?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/102?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-1@catalystbrief.girapphe.com
DTSTAMP:20261117T024426Z
LAST-MODIFIED:20261117T024426Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:PDUFA: Apnimed\, Inc. (APMD) — Oxnimbi (AD109)
DESCRIPTION:FDA PDUFA goal date for Oxnimbi (aroxybutynin and atomoxetine) 
 oral NDA.\nSource: https://www.sec.gov/Archives/edgar/data/1745648/0001193
 12526462171/apmd-ex99_1.htm\nhttps://catalystbrief.girapphe.com/e/1?lang=e
 n\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/1?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-15@catalystbrief.girapphe.com
DTSTAMP:20261117T061545Z
LAST-MODIFIED:20261117T061545Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Beijing Suncadia Pharmaceuticals Co.\, Ltd — SHR-1918/ S
 HR-1918 placebo [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Study of SHR-1918 In Participants
  With Hypertriglyceridemia.\nSource: https://clinicaltrials.gov/study/NCT0
 7349615\nhttps://catalystbrief.girapphe.com/e/15?lang=en\nNot investment a
 dvice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/15?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-17@catalystbrief.girapphe.com
DTSTAMP:20261117T061546Z
LAST-MODIFIED:20261117T061546Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Merz Therapeutics GmbH — Xeomin [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Clinical Trial to Evaluate Effica
 cy and Safety of Xeomin® Injections for Preventing Chronic Migraine.\nSou
 rce: https://clinicaltrials.gov/study/NCT07018713\nhttps://catalystbrief.g
 irapphe.com/e/17?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/17?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-19@catalystbrief.girapphe.com
DTSTAMP:20261117T061546Z
LAST-MODIFIED:20261117T061546Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Seattle Project Corporation — GRT-C901 [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Study of a Patient-Specific Neoan
 tigen Vaccine in Combination With Immune Checkpoint Blockade for Patients 
 With Metastatic Colorectal Cancer.\nSource: https://clinicaltrials.gov/stu
 dy/NCT05141721\nhttps://catalystbrief.girapphe.com/e/19?lang=en\nNot inves
 tment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/19?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-28@catalystbrief.girapphe.com
DTSTAMP:20261117T061547Z
LAST-MODIFIED:20261117T061547Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: AbbVie — Risankizumab SC [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Assess Adverse Events an
 d Change in Disease Activity of Risankizumab Subcutaneous Induction Treatm
 ent for Moderately to Severely Active Crohn's Disease..\nSource: https://c
 linicaltrials.gov/study/NCT06063967\nhttps://catalystbrief.girapphe.com/e/
 28?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/28?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-37@catalystbrief.girapphe.com
DTSTAMP:20261117T061549Z
LAST-MODIFIED:20261117T061549Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Pierre Fabre Medicament — Encorafenib and Binimetinib [M
 ar 2027]
DESCRIPTION:Phase 3 primary completion: Adjuvant Encorafenib and Binimetini
 b in High-risk Stage II Melanoma With a BRAF Mutation..\nSource: https://c
 linicaltrials.gov/study/NCT05270044\nhttps://catalystbrief.girapphe.com/e/
 37?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/37?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-46@catalystbrief.girapphe.com
DTSTAMP:20261117T061550Z
LAST-MODIFIED:20261117T061550Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Bristol-Myers Squibb — Nivolumab [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Study of Nivolumab Combined With 
 Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Can
 cer.\nSource: https://clinicaltrials.gov/study/NCT03873402\nhttps://cataly
 stbrief.girapphe.com/e/46?lang=en\nNot investment advice. Dates may change
 .
URL:https://catalystbrief.girapphe.com/e/46?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-57@catalystbrief.girapphe.com
DTSTAMP:20261117T061552Z
LAST-MODIFIED:20261117T061552Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: AbbVie — Upadacitinib [Mar 2027]
DESCRIPTION:Phase 3 primary completion: Program to Assess Adverse Events an
 d Change in Disease Activity of Oral Upadacitinib in Adult Participants Wi
 th Moderate to Severe Systemic Lupus Erythematosus.\nSource: https://clini
 caltrials.gov/study/NCT05843643\nhttps://catalystbrief.girapphe.com/e/57?l
 ang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/57?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-61@catalystbrief.girapphe.com
DTSTAMP:20261117T061553Z
LAST-MODIFIED:20261117T061553Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Novo Nordisk A/S — CagriSema (Cagrilintide B and Semaglu
 tide I) [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Research Study to Look at How Wel
 l CagriSema Helps People Living With Obesity Lose Weight and Maintain Weig
 ht Loss in the Long-term.\nSource: https://clinicaltrials.gov/study/NCT070
 11667\nhttps://catalystbrief.girapphe.com/e/61?lang=en\nNot investment adv
 ice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/61?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-75@catalystbrief.girapphe.com
DTSTAMP:20261117T061555Z
LAST-MODIFIED:20261117T061555Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Anhui Zhifei Longcom Biologic Pharmacy Co.\, Ltd. — quad
 rivalent recombinant norovirus vaccine (Pichia pastoris) [Mar 2027]
DESCRIPTION:Phase 3 primary completion: Clinical Trial of Protective Effica
 cy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris).\nSourc
 e: https://clinicaltrials.gov/study/NCT06524947\nhttps://catalystbrief.gir
 apphe.com/e/75?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/75?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-78@catalystbrief.girapphe.com
DTSTAMP:20261117T061555Z
LAST-MODIFIED:20261117T061555Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Fujian Shengdi Pharmaceutical Co.\, Ltd. — HRS9531 injec
 tion [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Study Comparing the Efficacy and 
 Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Ob
 esity.\nSource: https://clinicaltrials.gov/study/NCT07285902\nhttps://cata
 lystbrief.girapphe.com/e/78?lang=en\nNot investment advice. Dates may chan
 ge.
URL:https://catalystbrief.girapphe.com/e/78?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-79@catalystbrief.girapphe.com
DTSTAMP:20261117T061555Z
LAST-MODIFIED:20261117T061555Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Madrigal Pharmaceuticals\, Inc. — Resmetirom [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Phase 3 Study to Evaluate Safety 
 and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fat
 ty Liver Disease (NAFLD)\, MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAF
 LD-OLE).\nSource: https://clinicaltrials.gov/study/NCT04951219\nhttps://ca
 talystbrief.girapphe.com/e/79?lang=en\nNot investment advice. Dates may ch
 ange.
URL:https://catalystbrief.girapphe.com/e/79?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-80@catalystbrief.girapphe.com
DTSTAMP:20261117T061556Z
LAST-MODIFIED:20261117T061556Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Viatris Innovation GmbH — Cenerimod [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Research Study to Evaluate the Ef
 fects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupu
 s Erythematosus.\nSource: https://clinicaltrials.gov/study/NCT05648500\nht
 tps://catalystbrief.girapphe.com/e/80?lang=en\nNot investment advice. Date
 s may change.
URL:https://catalystbrief.girapphe.com/e/80?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-87@catalystbrief.girapphe.com
DTSTAMP:20261117T061557Z
LAST-MODIFIED:20261117T061557Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Hoffmann-La Roche — Atezolizumab [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Study Evaluating the Efficacy and
  Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for 
 Participants With HER2-Positive Breast Cancer at High Risk of Recurrence F
 ollowing Preoperative Therapy.\nSource: https://clinicaltrials.gov/study/N
 CT04873362\nhttps://catalystbrief.girapphe.com/e/87?lang=en\nNot investmen
 t advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/87?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-91@catalystbrief.girapphe.com
DTSTAMP:20261117T061557Z
LAST-MODIFIED:20261117T061557Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Aragon Pharmaceuticals\, Inc. — Apalutamide [Mar 2027]
DESCRIPTION:Phase 3 primary completion: An Efficacy and Safety Study of JNJ
 -56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Pr
 imary Radiation Therapy: ATLAS.\nSource: https://clinicaltrials.gov/study/
 NCT02531516\nhttps://catalystbrief.girapphe.com/e/91?lang=en\nNot investme
 nt advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/91?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-100@catalystbrief.girapphe.com
DTSTAMP:20261117T121547Z
LAST-MODIFIED:20261117T121547Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Novartis Pharmaceuticals — Ianalumab [Mar 2027]
DESCRIPTION:Phase 3 primary completion: Phase 3 Study to Evaluate Two Regim
 ens of Ianalumab on Top of Standard-of-care Therapy in Patients With Syste
 mic Lupus Erythematosus (SIRIUS-SLE 1).\nSource: https://clinicaltrials.go
 v/study/NCT05639114\nhttps://catalystbrief.girapphe.com/e/100?lang=en\nNot
  investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/100?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-105@catalystbrief.girapphe.com
DTSTAMP:20261117T121610Z
LAST-MODIFIED:20261117T121610Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Merz Therapeutics GmbH — Xeomin [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Clinical Trial to Evaluate Effica
 cy and Safety of Xeomin® Injections for Preventing Episodic Migraine.\nSo
 urce: https://clinicaltrials.gov/study/NCT07018700\nhttps://catalystbrief.
 girapphe.com/e/105?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/105?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-2@catalystbrief.girapphe.com
DTSTAMP:20261117T024426Z
LAST-MODIFIED:20261117T024426Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:PDUFA: Aquestive Therapeutics\, Inc. (AQST) — Anaphylm (dibutepin
 ephrine)
DESCRIPTION:FDA PDUFA goal date for Class 2 resubmission of Anaphylm sublin
 gual film NDA.\nSource: https://www.sec.gov/Archives/edgar/data/1398733/00
 0139873326000079/jefferiesglobalhealthcar.htm\nhttps://catalystbrief.girap
 phe.com/e/2?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/2?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-3@catalystbrief.girapphe.com
DTSTAMP:20261117T024426Z
LAST-MODIFIED:20261117T024426Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:PDUFA: Unicycive Therapeutics\, Inc. (UNCY) — oxylanthanum carbon
 ate (OLC)
DESCRIPTION:FDA PDUFA target action date for oxylanthanum carbonate (OLC) N
 DA resubmission.\nSource: https://www.sec.gov/Archives/edgar/data/1766140/
 000121390026120261/ea031236501ex99-1.htm\nhttps://catalystbrief.girapphe.c
 om/e/3?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/3?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-12@catalystbrief.girapphe.com
DTSTAMP:20261117T061545Z
LAST-MODIFIED:20261117T061545Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: Bayer — Finerenone (Kerendia\, BAY94-8862) [Apr 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Learn More About How Wel
 l the Study Treatment Finerenone Works\, How Safe it is\, How it Moves Int
 o\, Through\, and Out of the Body\, and the Effects it Has on the Body Whe
 n Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children 
 With Chronic Kidney Disease and Proteinuria.\nSource: https://clinicaltria
 ls.gov/study/NCT05196035\nhttps://catalystbrief.girapphe.com/e/12?lang=en\
 nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/12?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-16@catalystbrief.girapphe.com
DTSTAMP:20261117T061842Z
LAST-MODIFIED:20261117T061842Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: Novartis Pharmaceuticals — Ianalumab [Apr 2027]
DESCRIPTION:Phase 3 primary completion: Phase 3 Study to Evaluate Two Regim
 ens of Ianalumab on Top of Standard-of-care Therapy in Patients With Syste
 mic Lupus Erythematosus (SIRIUS-SLE 1).\nSource: https://clinicaltrials.go
 v/study/NCT05624749\nhttps://catalystbrief.girapphe.com/e/16?lang=en\nNot 
 investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/16?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-22@catalystbrief.girapphe.com
DTSTAMP:20261117T061546Z
LAST-MODIFIED:20261117T061546Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: RHEACELL GmbH & Co. KG — allo-APZ2-CVU [Apr 2027]
DESCRIPTION:Phase 3 primary completion: Allogeneic ABCB5-positive Dermal Me
 senchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)
 .\nSource: https://clinicaltrials.gov/study/NCT06489028\nhttps://catalystb
 rief.girapphe.com/e/22?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/22?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-25@catalystbrief.girapphe.com
DTSTAMP:20261117T061547Z
LAST-MODIFIED:20261117T061547Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: Sanofi — Isatuximab SAR650984 [Apr 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Investigate the Clinical
  Benefit of Isatuximab in Combination With Bortezomib\, Lenalidomide and D
 examethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible 
 for Transplant.\nSource: https://clinicaltrials.gov/study/NCT03319667\nhtt
 ps://catalystbrief.girapphe.com/e/25?lang=en\nNot investment advice. Dates
  may change.
URL:https://catalystbrief.girapphe.com/e/25?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-39@catalystbrief.girapphe.com
DTSTAMP:20261117T061842Z
LAST-MODIFIED:20261117T061842Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: Acerta Pharma BV — acalabrutinib [Apr 2027]
DESCRIPTION:Phase 3 primary completion: A Combination of Acalabrutinib With
  R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312).\
 nSource: https://clinicaltrials.gov/study/NCT03836261\nhttps://catalystbri
 ef.girapphe.com/e/39?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/39?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-47@catalystbrief.girapphe.com
DTSTAMP:20261117T061843Z
LAST-MODIFIED:20261117T061843Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: Amgen — Maridebart Cafraglutide [Apr 2027]
DESCRIPTION:Phase 3 primary completion: Evaluation of Maridebart Cafragluti
 de in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity
  or Are Overweight.\nSource: https://clinicaltrials.gov/study/NCT06987695\
 nhttps://catalystbrief.girapphe.com/e/47?lang=en\nNot investment advice. D
 ates may change.
URL:https://catalystbrief.girapphe.com/e/47?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-59@catalystbrief.girapphe.com
DTSTAMP:20261117T061552Z
LAST-MODIFIED:20261117T061552Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: MediciNova — MN-166 [Apr 2027]
DESCRIPTION:Phase 3 primary completion: Evaluation of MN-166 (Ibudilast) fo
 r 12 Months Followed by an Open-label Extension for 6 Months in Patients W
 ith ALS.\nSource: https://clinicaltrials.gov/study/NCT04057898\nhttps://ca
 talystbrief.girapphe.com/e/59?lang=en\nNot investment advice. Dates may ch
 ange.
URL:https://catalystbrief.girapphe.com/e/59?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-69@catalystbrief.girapphe.com
DTSTAMP:20261117T061554Z
LAST-MODIFIED:20261117T061554Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: Almirall\, S.A. — Lebrikizumab [Apr 2027]
DESCRIPTION:Phase 3 primary completion: A Study of Lebrikizumab Treatment i
 n Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis.\nSourc
 e: https://clinicaltrials.gov/study/NCT06526182\nhttps://catalystbrief.gir
 apphe.com/e/69?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/69?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-70@catalystbrief.girapphe.com
DTSTAMP:20261117T061554Z
LAST-MODIFIED:20261117T061554Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: Innovent Biologics Technology Limited (Shanghai R&D Center
 ) — Febuxostat [Apr 2027]
DESCRIPTION:Phase 3 primary completion: Tigulixostat (IBI128) vs Febuxostat
  in Gout.\nSource: https://clinicaltrials.gov/study/NCT07414394\nhttps://c
 atalystbrief.girapphe.com/e/70?lang=en\nNot investment advice. Dates may c
 hange.
URL:https://catalystbrief.girapphe.com/e/70?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-88@catalystbrief.girapphe.com
DTSTAMP:20261117T061557Z
LAST-MODIFIED:20261117T061557Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: AbbVie — Mirvetuximab soravtansine plus Bevacizumab [Apr
  2027]
DESCRIPTION:Phase 3 primary completion: Mirvetuximab Soravtansine With Beva
 cizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial
  Ovarian\, Fallopian Tube\, or Peritoneal Cancer.\nSource: https://clinica
 ltrials.gov/study/NCT05445778\nhttps://catalystbrief.girapphe.com/e/88?lan
 g=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/88?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-20@catalystbrief.girapphe.com
DTSTAMP:20261117T061546Z
LAST-MODIFIED:20261117T061546Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: Mylan Pharmaceuticals Inc — Transdermal system containin
 g progestin [May 2027]
DESCRIPTION:Phase 3 primary completion: Study to Evaluate Contraceptive Eff
 icacy and Safety of a Progestin Only Patch in Women of Childbearing Potent
 ial.\nSource: https://clinicaltrials.gov/study/NCT06672016\nhttps://cataly
 stbrief.girapphe.com/e/20?lang=en\nNot investment advice. Dates may change
 .
URL:https://catalystbrief.girapphe.com/e/20?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-43@catalystbrief.girapphe.com
DTSTAMP:20261117T061549Z
LAST-MODIFIED:20261117T061549Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: Novo Nordisk A/S — Cagrilintide [May 2027]
DESCRIPTION:Phase 3 primary completion: Weight Loss in People Living With O
 verweight or Obesity Following Treatment With Cagrilintide.\nSource: https
 ://clinicaltrials.gov/study/NCT07220642\nhttps://catalystbrief.girapphe.co
 m/e/43?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/43?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-67@catalystbrief.girapphe.com
DTSTAMP:20261117T061553Z
LAST-MODIFIED:20261117T061553Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: AstraZeneca — Trastuzumab deruxtecan [May 2027]
DESCRIPTION:Phase 3 primary completion: Trastuzumab Deruxtecan (T-DXd) With
  or Without Pertuzumab Versus Taxane\, Trastuzumab and Pertuzumab in HER2-
 positive Metastatic Breast Cancer (DESTINY-Breast09).\nSource: https://cli
 nicaltrials.gov/study/NCT04784715\nhttps://catalystbrief.girapphe.com/e/67
 ?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/67?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-85@catalystbrief.girapphe.com
DTSTAMP:20261117T061556Z
LAST-MODIFIED:20261117T061556Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: Sanofi — Frexalimab [May 2027]
DESCRIPTION:Phase 3 primary completion: Efficacy and Safety Studies of Frex
 alimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis.\n
 Source: https://clinicaltrials.gov/study/NCT06141473\nhttps://catalystbrie
 f.girapphe.com/e/85?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/85?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-86@catalystbrief.girapphe.com
DTSTAMP:20261117T061556Z
LAST-MODIFIED:20261117T061556Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: Sun Pharmaceutical Industries\, Inc. — CTP-543 [May 2027
 ]
DESCRIPTION:Phase 3 primary completion: Extension Study to Evaluate Safety 
 and Efficacy of CTP-543 in Adults With Alopecia Areata.\nSource: https://c
 linicaltrials.gov/study/NCT03898479\nhttps://catalystbrief.girapphe.com/e/
 86?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/86?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-95@catalystbrief.girapphe.com
DTSTAMP:20261117T061558Z
LAST-MODIFIED:20261117T061558Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: Novartis Pharmaceuticals — Inclisiran sodium 300 mg [May
  2027]
DESCRIPTION:Phase 3 primary completion: Study of Inclisiran to Prevent Card
 iovascular (CV) Events in Participants With Established Cardiovascular Dis
 ease.\nSource: https://clinicaltrials.gov/study/NCT05030428\nhttps://catal
 ystbrief.girapphe.com/e/95?lang=en\nNot investment advice. Dates may chang
 e.
URL:https://catalystbrief.girapphe.com/e/95?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-101@catalystbrief.girapphe.com
DTSTAMP:20261117T121553Z
LAST-MODIFIED:20261117T121553Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: Sichuan Kelun-Biotech Biopharmaceutical Co.\, Ltd. — SKB
 264 [May 2027]
DESCRIPTION:Phase 3 primary completion: A Study of SKB264 in Combination Wi
 th Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor
  Receptor (EGFR) Mutations\, Locally Advanced or Metastatic Non-Squamous N
 on-Small Cell Lung Cancer.\nSource: https://clinicaltrials.gov/study/NCT06
 670196\nhttps://catalystbrief.girapphe.com/e/101?lang=en\nNot investment a
 dvice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/101?lang=en
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:event-4@catalystbrief.girapphe.com
DTSTAMP:20261117T024426Z
LAST-MODIFIED:20261117T024426Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Readout: Biohaven Ltd. (BHVN) — Taldefgrobep [H2 2027]
DESCRIPTION:Phase 2 topline data expected (monotherapy and GLP-1 combinatio
 n arms).\nSource: https://www.sec.gov/Archives/edgar/data/1935979/00019359
 7926000096/biohavencorporatepresent.htm\nhttps://catalystbrief.girapphe.co
 m/e/4?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/4?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
